Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

219 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Long-term outcomes in patients with muscle-invasive bladder cancer after selective bladder-preserving combined-modality therapy: a pooled analysis of Radiation Therapy Oncology Group protocols 8802, 8903, 9506, 9706, 9906, and 0233.
Mak RH, Hunt D, Shipley WU, Efstathiou JA, Tester WJ, Hagan MP, Kaufman DS, Heney NM, Zietman AL. Mak RH, et al. Among authors: kaufman ds. J Clin Oncol. 2014 Dec 1;32(34):3801-9. doi: 10.1200/JCO.2014.57.5548. Epub 2014 Nov 3. J Clin Oncol. 2014. PMID: 25366678 Free PMC article.
Expression of the epidermal growth factor receptor and Her-2 are predictors of favorable outcome and reduced complete response rates, respectively, in patients with muscle-invading bladder cancers treated by concurrent radiation and cisplatin-based chemotherapy: a report from the Radiation Therapy Oncology Group.
Chakravarti A, Winter K, Wu CL, Kaufman D, Hammond E, Parliament M, Tester W, Hagan M, Grignon D, Heney N, Pollack A, Sandler H, Shipley W. Chakravarti A, et al. Int J Radiat Oncol Biol Phys. 2005 Jun 1;62(2):309-17. doi: 10.1016/j.ijrobp.2004.09.047. Int J Radiat Oncol Biol Phys. 2005. PMID: 15890569
Selective bladder preservation by trimodality therapy for patients with muscularis propria-invasive bladder cancer and who are cystectomy candidates--the Massachusetts General Hospital and Radiation Therapy Oncology Group experiences.
Shipley WU, Zietman AL, Kaufman DS, Coen JJ, Sandler HM. Shipley WU, et al. Among authors: kaufman ds. Semin Radiat Oncol. 2005 Jan;15(1):36-41. doi: 10.1016/j.semradonc.2004.07.008. Semin Radiat Oncol. 2005. PMID: 15662605 Review.
Bladder-sparing approaches to invasive disease.
Efstathiou JA, Zietman AL, Kaufman DS, Heney NM, Coen JJ, Shipley WU. Efstathiou JA, et al. Among authors: kaufman ds. World J Urol. 2006 Nov;24(5):517-29. doi: 10.1007/s00345-006-0114-y. World J Urol. 2006. PMID: 17082940 Review.
Phase I-II RTOG study (99-06) of patients with muscle-invasive bladder cancer undergoing transurethral surgery, paclitaxel, cisplatin, and twice-daily radiotherapy followed by selective bladder preservation or radical cystectomy and adjuvant chemotherapy.
Kaufman DS, Winter KA, Shipley WU, Heney NM, Wallace HJ 3rd, Toonkel LM, Zietman AL, Tanguay S, Sandler HM. Kaufman DS, et al. Urology. 2009 Apr;73(4):833-7. doi: 10.1016/j.urology.2008.09.036. Epub 2008 Dec 18. Urology. 2009. PMID: 19100600 Clinical Trial.
219 results